State Street Corp Angion Biomedica Corp. Transaction History

State Street Corp

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 15, 2022	SELL	$0.94 - $1.23 $2,820 - $3,690	-3,000 Reduced 19.11%	12,700 $12,000
Q2 2022 Aug 15, 2022	SELL	$1.1 - $2.23 $208,765 - $423,225	-189,787 Reduced 92.36%	15,700 $18,000
Q1 2022 May 16, 2022	SELL	$1.72 - $2.96 $36,508 - $62,828	-21,226 Reduced 9.36%	205,487 $436,000
Q4 2021 Feb 14, 2022	BUY	$2.35 - $9.95 $157,074 - $665,058	66,840 Added 41.81%	226,713 $657,000
Q3 2021 Nov 15, 2021	BUY	$9.31 - $13.25 $693,297 - $986,701	74,468 Added 87.19%	159,873 $1.56 Million
Q2 2021 Aug 16, 2021	BUY	$13.02 - $17.83 $499,968 - $684,671	38,400 Added 81.69%	85,405 $1.11 Million
Q1 2021 May 17, 2021	BUY	$15.01 - $25.74 $705,545 - $1.21 Million	47,005 New	47,005 $849,000

Ticker ANGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,113,300
Description
Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company's lead product candidate is ANG-3070, an oral tyrosine kinase receptor inhibitor in development as a treatment for fibrotic diseases, primaril...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.